BioNTech SE (BNTX)

NMS – Real vaqt narxi. Valyuta: USD

93.66

+0.32 (0.34%)

Yopilishda: May 12, 2026, 4:00 PM EDT

95.18

+1.52 (1.62%)

Bozordan keyin: May 12, 2026, 7:56 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

BioNTech SE (BNTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

BioNTech SE (BNTX)

BioNTech Announces New ADS Repurchase Program

BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology Plans

Germany says vaccine supply secure despite BioNTech production loss

BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript

BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

Videolar

Press-relizlar

BioNTech Announces New ADS Repurchase Program

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

Search stocks

BioNTech SE (BNTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

BioNTech SE (BNTX)

BioNTech Announces New ADS Repurchase Program

BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology Plans

Germany says vaccine supply secure despite BioNTech production loss

BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript

BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

Videolar

Press-relizlar

BioNTech Announces New ADS Repurchase Program

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer